- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Bicara Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.05. | Cantor Fitzgerald reiterates Bicara Therapeutics stock rating | 4 | Investing.com | ||
| 21.05. | Bicara Therapeutics meldet vielversprechende Dreijahres-Überlebensdaten bei Krebstherapie | 1 | Investing.com Deutsch | ||
| 21.05. | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | 131 | GlobeNewswire (Europe) | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| 21.05. | Bicara Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.05. | Bicara Therapeutics hires Replimune, Sanofi alum as chief commercial officer | 36 | FiercePharma | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.05. | Citizens reiterates Bicara Therapeutics stock rating on trial progress | 1 | Investing.com | ||
| 12.05. | Bicara Therapeutics: Citizens bestätigt "Market Outperform"-Rating nach Studienfortschritten | 1 | Investing.com Deutsch | ||
| 11.05. | Bicara Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Stifel cuts Bicara Therapeutics stock price target on estimates | 4 | Investing.com | ||
| 11.05. | Bicara plans Q3 alternative dosing study of ~150-200 patients as it targets mid-2027 interim analysis | 2 | Seeking Alpha | ||
| 11.05. | Bicara Q1 2026 slides: FICERA data shines amid earnings miss | 1 | Investing.com | ||
| 11.05. | Bicara Therapeutics GAAP EPS of -$0.93 misses by $0.28 | 1 | Seeking Alpha | ||
| 11.05. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | 582 | GlobeNewswire (Europe) | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| 11.05. | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Guggenheim initiates Bicara Therapeutics stock with buy rating | 1 | Investing.com | ||
| 11.05. | Guggenheim startet Coverage für Bicara Therapeutics mit Kaufempfehlung | - | Investing.com Deutsch | ||
| 04.05. | Bicara Therapeutics Inc.: Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET | 2 | GlobeNewswire (USA) | ||
| 03.04. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 108,12 | -7,16 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | +1,60 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | +2,67 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | +3,40 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | -0,05 % | Apogee Therapeutics vor Übernahme: sharedealsPlus-Tipp wird zum Multibagger | Nachdem wir die Aktie von Apogee Therapeutics bereits im vergangenen Jahr zu Preisen von rund 40 US$ als heißen Buyout-Kandidaten vorgestellt hatten und sich ihr Kurs zwischenzeitlich mehr als verdoppeln... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | -0,52 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | -1,81 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | +2,01 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen | |
| QIAGEN | 34,315 | -0,59 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,450 | +4,35 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,720 | +3,68 % | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | ||
| PROKIDNEY | 1,830 | +7,65 % | ProKidney Appoints Kenneth Locke as Chief Technical Officer | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| HUMACYTE | 0,709 | +14,29 % | Humacyte, Inc: Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was... ► Artikel lesen | |
| ERASCA | 15,940 | +6,62 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
Das Unternehmen BICARA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,01 % bei einem Aktienkurs von 26,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.